8.71 USD
▼-0.25-2.79%
盘后 8.55 -1.84%
2026-11-19
市值
$2.92B
市盈率
91.69
EPS
0.09
股息率
—
52 周区间
6.28 – 13.11
成交量
221.53K
Beta
0.63
目标价
19.66
52W 低 6.2852W 高 13.11
价格走势
公司简介
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ...
关联新闻
- Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion
Australia's Telix Pharmaceuticals said on Monday it has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis.